Related Experiment Videos
Antisense DNAs as targeted therapeutics for cancer: no longer a dream
1Cellular Biochemistry Section, BRL, CCR, National Cancer Institute, NIH, Bethesda, MD 20892-1750, USA. ChoChung@helix.nih.gov
Abstract:
Progress in antisense technology has been rapid, and the traditional antisense inhibition of gene expression has now been viewed at a genomic scale. This global view has led to a deeper understanding of the mechanism of action, the elimination of non-specific and undesirable side effects and, ultimately, greater efficacy and reduced toxicity for nucleic acid medicines. Several antisense oligonucleotides are in clinical trials; these are well tolerated and have therapeutic potential. Antisense oligonucleotides are promising molecular medicines with potential to treat human cancer in the foreseeable future.
Insights
Antisense technology has advanced rapidly, enabling genomic-scale gene expression inhibition. This progress enhances nucleic acid medicine efficacy and reduces toxicity, showing promise for treating cancer.
Area of Science:
- Molecular Biology
- Genetics
- Pharmacology
Background:
- Antisense technology has evolved significantly, moving from targeted gene inhibition to a genomic scale approach.
- This shift provides a comprehensive understanding of antisense oligonucleotide (ASO) mechanisms.
- Early ASOs faced challenges with specificity and side effects, limiting their therapeutic application.
Purpose of the Study:
- To review the advancements in antisense technology and its application in medicine.
- To highlight the improved understanding of ASO mechanisms of action.
- To assess the therapeutic potential of ASOs, particularly in cancer treatment.
Main Methods:
- Review of current literature on antisense technology and oligonucleotide therapeutics.
- Analysis of data from preclinical and clinical studies involving ASOs.
- Evaluation of ASO efficacy, safety, and toxicity profiles.
Main Results:
- Genomic-scale analysis has deepened the understanding of ASO mechanisms.
- Improved ASO design has led to the elimination of non-specific effects and reduced toxicity.
- Several ASOs are currently in clinical trials and demonstrate good tolerability.
- ASOs show significant therapeutic potential for various diseases, including cancer.
Conclusions:
- Antisense technology has matured, offering highly effective and safe nucleic acid medicines.
- Antisense oligonucleotides represent a promising class of molecular therapeutics.
- ASOs hold considerable potential for treating human cancers in the near future.